NASDAQ : GYRE
Gyre Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.41 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 679.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 501.54M |
| Enterprise Value | 430.16M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 106.03M |
| Shares Outstanding | 106.03M |
| Shares Change (YoY) | -1.16% |
| Shares Change (QoQ) | +10.14% |
| Owned by Insiders (%) | 5.74% |
| Owned by Institutions (%) | 8.22% |
| Float | 35.94M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.57 |
| Forward PS | 8.66 |
| PB Ratio | 4.65 |
| P/TBV Ratio | 4.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.26 |
| Quick Ratio | 3.59 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -17.44% |
| Return on Assets (ROA) | -5.42% |
| Return on Invested Capital (ROIC) | -16.81% |
| Return on Capital Employed (ROCE) | -8.95% |
| Weighted Average Cost of Capital (WACC) | 30.09% |
| Revenue Per Employee | $175,709 |
| Profits Per Employee | -$31,853 |
| Employee Count | 625 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.67 |
Taxes
| Measure | Value |
|---|
| Income Tax | 3.38M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 4.74 |
| 52-Week Price Change | -38.97% |
| 50-Day Moving Average | 6.69 |
| 200-Day Moving Average | 6.97 |
| Relative Strength Index (RSI) | 32.10 |
| Average Volume (20 Days) | 149,984 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.93M |
| Short Previous Month | 1.92M |
| Short % of Shares Out | 1.82% |
| Short % of Float | 5.36% |
| Short Ratio (days to cover) | 9.81 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 109.82M |
| Gross Profit | 103.01M |
| Operating Income | -15.26M |
| Pretax Income | -22.29M |
| Net Income | -19.91M |
| EBITDA | -12.13M |
| EBIT | -15.26M |
| Loss Per Share | -$0.22 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 74.80M |
| Total Debt | 3.42M |
| Net Cash | 71.38M |
| Net Cash Per Share | $0.67 |
| Equity (Book Value) | 164.92M |
| Book Value Per Share | 1.02 |
| Working Capital | 93.41M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -4.94M |
| Capital Expenditures | -1.17M |
| Depreciation & Amortization | 3.13M |
| Net Borrowing | n/a |
| Free Cash Flow | -6.11M |
| FCF Per Share | -$0.06 |
Margins
| Measure | Value |
|---|
| Gross Margin | 93.80% |
| Operating Margin | -13.90% |
| Pretax Margin | -20.30% |
| Profit Margin | -19.33% |
| EBITDA Margin | -11.05% |
| EBIT Margin | -13.90% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.16% |
| Shareholder Yield | 1.16% |
| Earnings Yield | -4.58% |
| FCF Yield | -1.22% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $18.67 |
| Price Target Difference | 294.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 55.25% |
| EPS Growth Forecast (3Y) | 119.68% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 11.85 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |